Rennova Health's Response to COVID-19

Financials

v3.25.0.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash $ 49,015 $ 499,470
Accounts receivable, net 3,087,420 3,110,969
Inventory 198,156 242,645
Prepaid expenses and other current assets 44,601 215,365
Income tax refunds receivable 837,460 837,460
Total current assets 6,944,959 6,363,162
Property and equipment, net 4,321,299 4,194,299
Intangible asset 259,443 259,443
Investment 8,192,476 9,016,072
Deposits 175,569 165,530
Right-of-use assets 359,194 574,256
Total assets 20,252,940 20,572,762
Current liabilities:    
Accounts payable (includes related party amounts of $97,311 and $47,636, respectively) 12,371,566 11,204,305
Accrued expenses 15,399,268 19,384,803
Income taxes payable 1,589,244 1,348,425
Current portion of notes payable 1,026,758 2,917,390
Current portion of loan payable, related party 2,168,000 2,995,000
Current portion of debentures 8,622,240
Current portion of right-of-use operating lease obligations 183,345 215,063
Derivative liability 455,336 455,336
Current liabilities of discontinued operations 9,312,174 2,165,595
Total current liabilities 42,505,691 49,308,157
Long-term liabilities:    
Accrued expenses 6,192,700
Debentures 8,222,240
Right-of-use operating lease obligations, net of current portion 175,849 359,193
Total liabilities 57,096,480 49,667,350
Commitments and contingencies
Stockholders’ deficit:    
Common stock, $0.0001 par value, 250,000,000,000 shares authorized, 40,551,322,257 and 29,084,322,257 shares issued and outstanding, respectively 4,055,132 2,908,432
Additional paid-in-capital 1,670,425,144 1,671,571,834
Accumulated deficit (1,711,306,941) (1,703,577,780)
Total Rennova’s stockholders’ deficit (36,823,749) (29,094,588)
Noncontrolling interest (19,791)
Total stockholders’ deficit (36,843,540) (29,094,588)
Total liabilities and stockholders’ deficit 20,252,940 20,572,762
Series H Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock, value
Series L Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock, value 2,500 2,500
Series M Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock, value 208 208
Series N Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock, value 24 29
Series O Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock, value 82 87
Series P Preferred Stock [Member]    
Stockholders’ deficit:    
Preferred stock, value 102 102
Related Party [Member]    
Current assets:    
Note receivable from related party 2,728,307 1,457,253
Current liabilities:    
Current portion of loan payable, related party $ 2,168,000 $ 2,995,000

Source

v3.25.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Net revenues $ 18,685,845 $ 13,036,172
Operating expenses:    
Direct costs of revenues 7,574,548 6,767,921
General and administrative expenses 9,435,031 7,217,405
Depreciation and amortization 310,528 469,371
Total operating expenses 17,320,107 14,454,697
Income (loss) from continuing operations before other income (expense), income taxes and net loss attributable to noncontrolling interest 1,365,738 (1,418,525)
Other income (expense):    
Other income, net 1,151,754 433,353
Gain from forgiveness of debt 200,000 334,819
Loss from legal settlements, net (755,117) (129,153)
Change in fair value of investment (823,596)
Interest expense (1,452,823) (2,257,544)
Total other income (expense), net (1,679,782) (1,618,525)
Net loss from continuing operations before income taxes, including noncontrolling interest (314,044) (3,037,050)
Provision for income taxes (239,834) (312,849)
Net loss from continuing operations, including noncontrolling interest (553,878) (3,349,899)
(Loss) income from discontinued operations (7,195,076) 56,844
Net loss, including noncontrolling interest (7,748,954) (3,293,055)
Net loss attributable to noncontrolling interest 19,793
Net loss attributable to Rennova (7,729,161) (3,293,055)
Deemed dividends (330,876,369)
Net loss available to common stockholders $ (7,729,161) $ (334,169,424)
Net loss per share of common stock available to common stockholders- basic and diluted    
Continuing operations - basic $ (0.00) $ (0.03)
Continuing operations - diluted (0.00) (0.03)
Discontinued operations - basic (0.00) 0.00
Discontinued operations - diluted (0.00) 0.00
Total basic (0.00) (0.03)
Total diluted $ (0.00) $ (0.03)
Weighted average number of shares of common stock outstanding during the period:    
Basic 32,825,519,517 9,992,238,468
Diluted 32,825,519,517 9,992,238,468

Source

v3.25.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss from continuing operations, including noncontrolling interest $ (553,878) $ (3,349,899)
Adjustments to reconcile net loss to net cash provided by (used in) operations:    
Depreciation and amortization 310,528 469,371
Non-cash interest income (90,653) (212,819)
Original issue discount on debt 50,000
Gain from forgiveness of debt (200,000) (334,819)
Net loss from legal settlements 755,117 129,153
Change in fair value of investment 823,596
Loss on disposal of equipment 1,650
Income from federal government provider relief funds (285,572) (595,692)
Changes in operating assets and liabilities:    
Accounts receivable 23,549 (343,446)
Inventory 44,489 37,868
Prepaid expenses and other current assets 84,172 (93,486)
Security deposits (10,039) 22,284
Change in right-of-use assets 215,062 247,018
Accounts payable 1,167,261 (6,704)
Accrued expenses 1,126,971 3,686,494
Change in right-of-use operating lease obligations (215,062) (247,018)
Income tax assets and liabilities 240,819 312,849
Net cash provided by (used in) operating activities of continuing operations 3,436,360 (227,196)
Net cash (used in) provided by operating activities of discontinued operations (48,497) 8,848
Net cash provided by (used in) operating activities 3,387,863 (218,348)
Cash flows from investing activities:    
Capital expenditures (350,934) (35,230)
Note receivable / receivable from related party (1,180,401) (869,961)
Net cash used in investing activities of continuing operations (1,531,335) (905,191)
Net cash from investing activities of discontinued operations
Net cash used in investing activities (1,531,335) (905,191)
Cash flows from financing activities:    
Proceeds from issuance of related party loans 580,000 1,050,000
Payments on related party loans (1,407,000) (182,000)
Proceeds from issuance of debentures 500,000
Payments of debentures (400,000) (150,000)
Payments on notes payable (1,079,983) (1,415,610)
Receivables paid under accounts receivable sales agreements (688,235)
Proceeds from federal government provider relief funds 284,339
Proceeds from issuances of Series P Preferred Stock 1,500,000
Cash paid for fractional shares in connection with reverse stock split (9)
Net cash (used in) provided by financing activities of continuing operations (2,306,983) 898,485
Net cash from financing activities of discontinued operations
Net cash (used in) provided by financing activities (2,306,983) 898,485
Net change in cash (450,455) (225,054)
Cash at beginning of period 499,470 724,524
Cash at end of period $ 49,015 $ 499,470

Source